|Bid||19.00 x 500|
|Ask||118.10 x 200|
|Day's Range||104.85 - 108.58|
|52 Week Range||80.69 - 126.89|
|Beta (3Y Monthly)||1.81|
|PE Ratio (TTM)||40.70|
|Earnings Date||Feb 25, 2019 - Mar 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||134.20|
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, Nov. 29, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Medtronic's (MDT) resolve to take over the Israel-based robotic surgical guidance systems company, Mazor Robotics, adheres to its goal to grow in the sphere of robotics spine surgery.
Hill Rom (HRC) sets sights on product innovation. In patient support systems, the company unveils Hill-Rom Envella Air Fluidized Therapy Bed.
Haemonetics (HAE) sees encouraging growth at the North America Plasma revenues on strong disposables along with growing software revenues.
Masimo announced today that a new consensus statement on postoperative anemia management was published in Anaesthesia by an international panel of clinicians specializing in patient blood management, which includes clear guidance on the use and benefits of noninvasive hemoglobin measurement.1 The statement, which discusses both spot-check and continuous measurement, references the Masimo Rad-67™ Pulse ...
Masimo Corporation (NASDAQ:MASI), which is in the medical equipment business, and is based in United States, saw a decent share price growth in the teens level on the NasdaqGS over Read More...
Masimo today announced that its management is scheduled to present at the Stifel 2018 Healthcare Conference at the Palace Hotel in New York on Wednesday, November 14, 2018 at 10:15 a.m.
Strong demand for its pulse oximeters powers another better-than-expected quarter for the maker of noninvasive monitoring technologies.
Masimo (MASI) delivered earnings and revenue surprises of 4.41% and 2.06%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Irvine, California-based company said it had net income of $1.02 per share. Earnings, adjusted for one-time gains and costs, came to 71 cents per share. The results surpassed Wall Street expectations. ...
Long-term growth prospects of the Medical Products industry looks promising despite certain short-term political conundrums.